ES2542842T3 - Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer - Google Patents

Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer Download PDF

Info

Publication number
ES2542842T3
ES2542842T3 ES02252414.4T ES02252414T ES2542842T3 ES 2542842 T3 ES2542842 T3 ES 2542842T3 ES 02252414 T ES02252414 T ES 02252414T ES 2542842 T3 ES2542842 T3 ES 2542842T3
Authority
ES
Spain
Prior art keywords
transfer agent
taurultam
taurolidine
administered
methylol transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02252414.4T
Other languages
English (en)
Spanish (es)
Inventor
H. Paul Redmond
Ruediger Stendel
Hanns Moehler
Rolf W. Pfirrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ed Geistlich Soehne AG fuer Chemische Industrie
Original Assignee
Ed Geistlich Soehne AG fuer Chemische Industrie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ed Geistlich Soehne AG fuer Chemische Industrie filed Critical Ed Geistlich Soehne AG fuer Chemische Industrie
Application granted granted Critical
Publication of ES2542842T3 publication Critical patent/ES2542842T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
ES02252414.4T 2001-04-03 2002-04-03 Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer Expired - Lifetime ES2542842T3 (es)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US28074801P 2001-04-03 2001-04-03
US280748P 2001-04-03
US28171001P 2001-04-06 2001-04-06
US28171101P 2001-04-06 2001-04-06
US28171201P 2001-04-06 2001-04-06
US28171301P 2001-04-06 2001-04-06
US281712P 2001-04-06
US281710P 2001-04-06
US281711P 2001-04-06
US281713P 2001-04-06
US28493401P 2001-04-20 2001-04-20
US28493301P 2001-04-20 2001-04-20
US284934P 2001-04-20
US284933P 2001-04-20

Publications (1)

Publication Number Publication Date
ES2542842T3 true ES2542842T3 (es) 2015-08-12

Family

ID=27569569

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02252414.4T Expired - Lifetime ES2542842T3 (es) 2001-04-03 2002-04-03 Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer
ES10009649.4T Expired - Lifetime ES2562827T3 (es) 2001-04-03 2002-04-03 Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10009649.4T Expired - Lifetime ES2562827T3 (es) 2001-04-03 2002-04-03 Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer

Country Status (5)

Country Link
US (1) US20030027818A1 (2)
EP (2) EP1247524B1 (2)
JP (2) JP2002363102A (2)
CA (2) CA2692295C (2)
ES (2) ES2542842T3 (2)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US8304390B2 (en) * 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US20070275955A1 (en) * 1997-07-31 2007-11-29 Ed. Geistlich Soehne Ag Method of treating tumors
US7345039B2 (en) * 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US6821968B2 (en) * 2001-09-26 2004-11-23 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Stable taurolidine electrolyte solutions
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7892530B2 (en) * 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
WO2002044394A2 (en) * 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
US20030092707A1 (en) * 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
ES2366617T3 (es) * 2003-04-21 2011-10-21 Epeius Biotechnologies Corporation Métodos y composiciones para el tratamiento de transtornos.
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US8236794B2 (en) * 2003-09-29 2012-08-07 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
BRPI0619370A2 (pt) * 2005-11-29 2011-09-27 Novartis Ag formulações de quinolinonas
ES2377206T3 (es) 2006-01-06 2012-03-23 Ed Geistlich Sohne Ag Fur Chemische Industrie Composiciones irradiadas y tratamiento de cánceres con radiación en combinación con taurolidina y/o taurultam
RU2468796C2 (ru) * 2006-09-07 2012-12-10 Эд. Гайстлих Зёне Аг Фюр Хемише Индустри Способ лечения рака костей
CN103118669B (zh) * 2010-06-01 2016-01-13 盖斯特里希医药公司 口服药物治疗方法和组合物
JP7064436B2 (ja) * 2015-08-31 2022-05-10 コーメディクス・インコーポレーテッド ナノファイバーウェブを用いる活性剤の送達
US20190381060A1 (en) 2016-01-11 2019-12-19 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
CA3111057A1 (en) * 2018-08-28 2020-02-05 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products
KR20210054544A (ko) * 2018-08-31 2021-05-13 코르메딕스, 인코포레이티드 포유류 체내의 myc-발현 종양에 대한 타우로리딘 치료
US20220323452A1 (en) * 2019-05-22 2022-10-13 Geistlich Pharma Ag Methods and compositions for inhibiting gapdh

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8617482D0 (en) 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
GB9005856D0 (en) * 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
GB9015108D0 (en) * 1990-07-09 1990-08-29 Geistlich Soehne Ag Chemical compositions
AU641529B2 (en) * 1990-07-30 1993-09-23 Bloomfield D.A. Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions
GB9600426D0 (en) * 1996-01-10 1996-03-13 Ed Geistlich Sohne A G Compositions
US5858990A (en) * 1997-03-04 1999-01-12 St. Elizabeth's Medical Center Fas ligand compositions for treatment of proliferative disorders
WO1998052573A1 (en) 1997-05-20 1998-11-26 Galenica Pharmaceuticals, Inc. Triterpene saponin analogs having adjuvant and immunostimulatory activity
WO1998052572A1 (en) * 1997-05-22 1998-11-26 Oklahoma Medical Research Foundation Use of taurolidine for treatment of leukemias
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
US6479481B1 (en) 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
JP2003515558A (ja) 1999-12-06 2003-05-07 ロード アイランド ホスピタル， ア ライフスパン パートナー 腫瘍を治療するためのメチロール含有化合物の使用
CA2363973C (en) * 2000-11-28 2009-03-10 Ed. Geistlich Sohne Ag Fur Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569

Also Published As

Publication number Publication date
JP2009138003A (ja) 2009-06-25
JP5232678B2 (ja) 2013-07-10
EP1247524A1 (en) 2002-10-09
ES2562827T3 (es) 2016-03-08
CA2379734C (en) 2010-06-29
US20030027818A1 (en) 2003-02-06
JP2002363102A (ja) 2002-12-18
CA2379734A1 (en) 2002-10-03
CA2692295A1 (en) 2002-10-03
EP2258373B1 (en) 2016-01-27
EP1247524B1 (en) 2015-06-24
CA2692295C (en) 2013-06-25
EP2258373A1 (en) 2010-12-08

Similar Documents

Publication Publication Date Title
ES2150889T1 (es) Una combinacion de glibenclamida-clorhidrato para el tratamiento de la diabetes mellitus de tipo ii.
DOP2022000100A (es) Agonista del receptor glp-1 y uso de este
AR005282A1 (es) Composición farmacéutica oral en la forma de un comprimido de unidades múltiples, uso de la misma para la preparación de medicamnetos, y procedimiento para su manufactura.
PA8542701A1 (es) Composición parenteral reconstituible
AR037255A1 (es) Composiciones farmaceuticas que contienen oxibutinina
ES2060199T3 (es) Forma galenica para administrar oralmente glipicida hipoglicemica.
AR111572A2 (es) Formas farmacéuticas que contienen vardenafilo
CO6220962A2 (es) Usos terapeuticos novedosos de 1-[2(2,4-dimetilfenilsulfanil)fenil]-piperazina
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
AR035863A1 (es) Ligandos receptores de melanocortina
UY26926A1 (es) Derivados de la quinolina y quinazolina
MX9203444A (es) Medicamentos.
GEP20063799B (en) Tropane derivatives useful in therapy
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
AR019053A1 (es) Uso de 2'2'-difluoronucleosidos para la preparacion de un medicamento y composicion farmaceutica y producto farmaceutico que los contienen
JP2009138003A5 (2)
UY27296A1 (es) Composición farmacéutica que contiene mosaprida y pancreatina
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
CA2379734A1 (en) Treatment of cancers
DK349889D0 (da) Anvendelse af polyacrylater til fremstilling af et laegemiddel
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
UY25798A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.
AR046951A1 (es) Moduladores de los receptores nucleares de hormonas esteroides triciclicos
ES2563068T3 (es) Tratamiento de esclerosis múltiple (MS) con Campath-1H